Crossmark

Efficacy and safety of maintenance therapy with anlotinib for advanced cholangiocarcinoma after first-line chemotherapy and the variations in efficacy based on different neutrophil-to-lymphocyte ratio (NLR)

Crossref DOI link: https://doi.org/10.1186/s12957-024-03472-9

Published Online: 2024-07-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Hui

Zhang, Jue

Gu, Lili
License Information

Text and Data Mining valid from 2024-07-29

Version of Record valid from 2024-07-29
More Information

Article History

Received: 5 March 2024

Accepted: 17 July 2024

First Online: 29 July 2024

Declarations

:

: Informed consent was obtained from all individual participants included in the study.

: All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study is approved by the Ethics Committee of Affiliated Jinling Hospital, Medical School of Nanjing University. Written informed consent was obtained.

: The authors declare no competing interests.

: The authors declare that there are no conflicts of interest regarding the publication of this paper.

Document is current

Any future updates will be listed below